What I have: cagrilintide · minus 20 °C.
I would like to understand the steps well enough to explain them to someone else.
I have access to a refrigerator with a logger and a freezer without one, which may be relevant.
Which parts of this are load-bearing and which parts are habit?
Whatever the refrigerated figure is, freezing does not simply extend it. minus 20 °C is 25 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. A frozen solution is not a slow solution: ice excludes solute, so the unfrozen fraction concentrates, the pH of the buffer shifts as one component crystallises first, and the damage happens during the transitions rather than during the hold. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.
Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
Sequence determines which pathways apply, so general statements are general.
Sequence decides which pathways are even available. Check the residues.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThis is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
At dilute concentrations, suspect adsorption before you suspect chemistry.
The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
Cold, dry, dark, still. Those four words cover most of the mitigation.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.